1. Home
  2. CING vs TVGN Comparison

CING vs TVGN Comparison

Compare CING & TVGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CING

Cingulate Inc.

BUY

Current Price

$4.98

Market Cap

59.3M

Sector

Health Care

ML Signal

BUY

Logo Tevogen Bio Holdings Inc.

TVGN

Tevogen Bio Holdings Inc.

HOLD

Current Price

$10.60

Market Cap

63.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CING
TVGN
Founded
2012
2020
Country
United States
United States
Employees
14
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
59.3M
63.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CING
TVGN
Price
$4.98
$10.60
Analyst Decision
Strong Buy
Hold
Analyst Count
2
1
Target Price
$34.50
N/A
AVG Volume (30 Days)
750.7K
40.1K
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.16
$0.14
52 Week High
$11.89
$12.00

Technical Indicators

Market Signals
Indicator
CING
TVGN
Relative Strength Index (RSI) 53.24 60.04
Support Level $4.69 $0.39
Resistance Level $5.35 $12.00
Average True Range (ATR) 0.61 1.64
MACD 0.13 0.16
Stochastic Oscillator 90.20 84.10

Price Performance

Historical Comparison
CING
TVGN

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

About TVGN Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Share on Social Networks: